At the time of data cutoff ( May @ , @ ) , @ ( @ % ) patients had disease progression in the gefitinib group compared with @ ( @ % ) in the placebo group ( hazard ratio @ , @ % CI @-@ ; p = @ ; median progression-free survival @ months in both groups -LSB- @ % CI @-@ in the gefitinib group and @-@ in the placebo group -RSB- ) .